2025 · 3rd Quarter (July 1 - Sep 30)

CERUS CORPORATION

Filed by INNOVATIVE FEDERAL STRATEGIES, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 8, 2025
Income: $40,000.00
Expenses: Not reported
Registrant: INNOVATIVE FEDERAL STRATEGIES, LLC
Client: CERUS CORPORATION
Filing UUID: 58fc63c1-a2ff-47b5-a561-5a782f36eb44
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R.4016/S.2572 Department of Defense Appropriations Bill, 2026, Title VI, all provisions related to blood safety. H.R.5304/S.2587 Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2026 - Title II, all provisions related to blood safety.

Literal federal measure citations: H.R.4016, S.2572, H.R.5304, S.2587

DEF · Defense

H.R.3838/S.2296 National Defense Authorization Act, 2026, Title XIV, all provisions related to blood safety.

Literal federal measure citations: H.R.3838, S.2296

HCR · Health Issues

Contacted officials regarding the Red Blood Cell Clinical Trial Program and blood safety issues.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.